You have full text access to this OnlineOpen article

Genetic Variation in the Paraoxonase-3 (PON3) Gene is Associated with Serum PON1 Activity

  1. Dharambir K. Sanghera1,*,
  2. Susan Manzi2,
  3. Ryan L. Minster1,
  4. Penny Shaw2,
  5. Amy Kao2,
  6. Franklin Bontempo3,
  7. M. Ilyas Kamboh1

Article first published online: 27 SEP 2007

DOI: 10.1111/j.1469-1809.2007.00400.x

Issue

Annals of Human Genetics

Annals of Human Genetics

Volume 72, Issue 1, pages 72–81, January 2008

Additional Information

How to Cite

Sanghera, D. K., Manzi, S., Minster, R. L., Shaw, P., Kao, A., Bontempo, F. and Kamboh, M. I. (2008), Genetic Variation in the Paraoxonase-3 (PON3) Gene is Associated with Serum PON1 Activity. Annals of Human Genetics, 72: 72–81. doi: 10.1111/j.1469-1809.2007.00400.x

Author Information

  1. 1

    Department of Human Genetics, Graduate School of Public Health

  2. 2

    Division of Rheumatology and Clinical Immunology, Lupus Center of Excellence, University of Pittsburgh, Pittsburgh

  3. 3

    Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh

* *Present address: Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City Correspondence to: M.Ilyas Kamboh, PhD, Department of Human Genetics, Graduate School of Public Health, Pittsburgh, PA 15261. Phone: 412-624-3066, Fax: 412-383-7844. E-mail: ikamboh@hgen.pitt.edu

Publication History

  1. Issue published online: 2 JAN 2008
  2. Article first published online: 27 SEP 2007
  3. Received: 14 July 2007 Accepted: 17 August 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (346K)

References

  • Aharoni, A., Gaidukov, L., Yagur, S., Toker, L., Silman, I. & Tawfik, D. S. (2004) Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc Natl Acad Sci U S A 101, 482–7.
  • Audikovszky, M., Pados, G., Seres, I., Harangi, M., Fulop, P., Katona, E., Illyes, L., Winkler, G., Katona, E. M. & Paragh, G. (2007) Orlistat increases serum paraoxonase activity in obese patients. Nutr Metab Cardiovasc Dis 17, 268–73.
  • Aviram, M., Billecke, S., Sorenson, R., Bisgaier, C., Newton, R., Rosenblat, M., Erogul, J., Hsu, C., Dunlop, C. & La Du, B. (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18, 1617–24.
  • Aviram, M., Rosenblat, M., Gaitini, D., Nitecki, S., Hoffman, A., Dornfeld, L., Volkova, N., Presser, D., Attias, J., Liker, H. & Hayek, T. (2004) Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 23, 423–33.
  • Boemi, M., Leviev, I., Sirolla, C., Pieri, C., Marra, M. & James, R. W. (2001) Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 155, 229–35.
  • Costa, L. G., Cole, T. B., Jarvik, G. P. & Furlong, C. E. (2003) Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 54, 371–92.
  • Delgado Alves, J., Ames, P. R., Donohue, S., Stanyer, L., Nourooz-Zadeh, J., Ravirajan, C. & Isenberg, D. A. (2002) Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46, 2686–94.
    Direct Link:
  • Draganov, D. I. & La Du, B. N. (2004) Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol 369, 78–88.
  • Draganov, D. I., Stetson, P. L., Watson, C. E., Billecke, S. S. & La Du, B. N. (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275, 33435–42.
  • Draganov, D. I., Teiber, J. F., Speelman, A., Osawa, Y., Sunahara, R. & La Du, B. N. (2005) Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46, 1239–47.
  • Durrington, P. N., Mackness, B. & Mackness, M. I. (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21, 473–80.
  • Esdaile, J. M., Abrahamowicz, M., Grodzicky, T., Li, Y., Panaritis, C., Du Berger, R., Cote, R., Grover, S. A., Fortin, P. R., Clarke, A. E. & Senecal, J. L. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44, 2331–7.
    Direct Link:
  • Hayem, G., Nicaise-Roland, P., Palazzo, E., De Bandt, M., Tubach, F., Weber, M. & Meyer, O. (2001) Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 10, 346–51.
  • Hochberg, M. C. (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40, 1725.
    Direct Link:
  • Jakubowski, H. (2000) Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 275, 3957–62.
  • Koch, M., Hering, S., Barth, C., Ehren, M., Enderle, M. D. & Pfohl, M. (2001) Paraoxonase 1 192 Gln/Arg gene polymorphism and cerebrovascular disease: interaction with type 2 diabetes. Exp Clin Endocrinol Diabetes 109, 141–5.
  • Lee, A. B., Godfrey, T., Rowley, K. G., Karschimkus, C. S., Dragicevic, G., Romas, E., Clemens, L., Wilson, A. M., Nikpour, M., Prior, D. L., Best, J. D. & Jenkins, A. J. (2006) Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Intern Med J 36, 237–43.
    Direct Link:
  • Mackness, B., Mackness, M. I., Arrol, S., Turkie, W., Julier, K., Abuasha, B., Miller, J. E., Boulton, A. J. & Durrington, P. N. (1998) Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139, 341–9.
  • Mackness, M. I., Arrol, S. & Durrington, P. N. (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286, 152–4.
  • Mackness, M. I., Peuchant, E., Dumon, M. F., Walker, C. H. & Clerc, M. (1989) Absence of “A”-esterase activity in the serum of a patient with Tangier disease. Clin Biochem 22, 475–8.
  • Mackness, M. I., Walker, C. H. & Carlson, L. A. (1987) Low A-esterase activity in serum of patients with fish-eye disease. Clin Chem 33, 587–8.
  • McElveen, J., Mackness, M. I., Colley, C. M., Peard, T., Warner, S. & Walker, C. H. (1986) Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 32, 671–3.
  • Mochizuki, H., Scherer, S. W., Xi, T., Nickle, D. C., Majer, M., Huizenga, J. J., Tsui, L. C. & Prochazka, M. (1998) Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213, 149–57.
  • Ng, C. J., Wadleigh, D. J., Gangopadhyay, A., Hama, S., Grijalva, V. R., Navab, M., Fogelman, A. M. & Reddy, S. T. (2001) Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276, 44444–9.
  • Primo-Parmo, S. L., Sorenson, R. C., Teiber, J. & La Du, B. N. (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33, 498–507.
  • Reddy, S. T., Wadleigh, D. J., Grijalva, V., Ng, C., Hama, S., Gangopadhyay, A., Shih, D. M., Lusis, A. J., Navab, M. & Fogelman, A. M. (2001) Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21, 542–7.
  • Roest, M., Van Himbergen, T. M., Barendrecht, A. B., Peeters, P. H., Van Der Schouw, Y. T. & Voorbij, H. A. (2007) Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Invest 37, 187–96.
    Direct Link:
  • Selzer, F., Sutton-Tyrrell, K., Fitzgerald, S., Tracy, R., Kuller, L. & Manzi, S. (2001) Vascular stiffness in women with systemic lupus erythematosus. Hypertension 37, 1075–82.
  • Shih, D. M., Gu, L., Xia, Y. R., Navab, M., Li, W. F., Hama, S., Castellani, L. W., Furlong, C. E., Costa, L. G., Fogelman, A. M. & Lusis, A. J. (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284–7.
  • Shih, D. M., Xia, Y. R., Wang, X. P., Wang, S. S., Bourquard, N., Fogelman, A. M., Lusis, A. J. & Reddy, S. T. (2007) Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res 100, 1200–7.
  • Sinnwell, J. P. & Schaid, D. J. (2005) Haplostats: Statistical analysis of haplotypes with traits and covariates when linkage phase is ambiguous. mayoresearch.mayo.edu/mayo/research/biostat/schaid.cfm .
  • Svenungsson, E., Jensen-Urstad, K., Heimburger, M., Silveira, A., Hamsten, A., De Faire, U., Witztum, J. L. & Frostegard, J. (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104, 1887–93.
  • Tan, E. M., Fritzler, M. J., McDougal, J. S., McDuffie, F. C., Nakamura, R. M., Reichlin, M., Reimer, C. B., Sharp, G. C., Schur, P. H., Wilson, M. R. & Winchester, R. J. (1982) Reference sera for antinuclear antibodies. I. Antibodies to native DNA, Sm, nuclear RNP, and SS-B/La. Arthritis Rheum 25, 1003–5.
    Direct Link:
  • Tripi, L. M., Manzi, S., Chen, Q., Kenney, M., Shaw, P., Kao, A., Bontempo, F., Kammerer, C. & Kamboh, M. I. (2006) Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum 54, 1928–39.
    Direct Link:
  • Vaarala, O., Alfthan, G., Jauhiainen, M., Leirisalo-Repo, M., Aho, K. & Palosuo, T. (1993) Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341, 923–5.
  • Watson, A. D., Berliner, J. A., Hama, S. Y., La Du, B. N., Faull, K. F., Fogelman, A. M. & Navab, M. (1995) Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96, 2882–91.
  • Zhao, J. H., Curtis, D. & Sham, P. C. (2000) Model-free analysis and permutation tests for allelic associations. Hum Hered 50, 133–9.
View Full Article (HTML) Get PDF (346K)